• Home

  • About Us

    • Company Profile

    • Development Process

    • Strength

    • Enterprise Culture

  • Products

    • Listed Products

    • Linked API

    • Pipeline

  • Custom Services

    • Process Transfer

    • Process Validation and Registration Declaration

    • Analysis and Testing

    • API Production

  • Blog

    • Company News

    • EHS Information

    • Industry News

  • Join us

    • Recruitment Posts

    • Employee Benefits

    • Employee Activities

  • Contact Us

确认
Blog

Blog

Company News

EHS Information

Industry News

Notice on the Procedures and Requirements for Submission of Materials for the Approval of Generic Names of Drugs

Notice on the Procedures and Requirements for Submission of Materials for the Approval of Generic Names of Drugs

03

2025

/

04

National Medical Products Administration Announcement on the Release of the Reference Drug List for Generic Drugs (No. 90, 2025)

National Medical Products Administration Announcement on the Release of the Reference Drug List for Generic Drugs (No. 90, 2025)

03

2025

/

04

Announcement of the National Medical Products Administration on Suspending the Import of 5 Drug Substances Including Glutathione from KYOWA HAKKO BIO CO., LTD. (No. 26 of 2025)

Announcement of the National Medical Products Administration on Suspending the Import of 5 Drug Substances Including Glutathione from KYOWA HAKKO BIO CO., LTD. (No. 26 of 2025)

01

2025

/

04

National Medical Products Administration Announcement on the Release of the Reference Drug List for Generic Drugs (No. 4, 2025)

01

2025

/

04

Interpretation of Matters Concerning the Implementation of the 2025 Edition of the Chinese Pharmacopoeia (I)

Interpretation of Matters Concerning the Implementation of the 2025 Edition of the Chinese Pharmacopoeia (I)

31

2025

/

03

Announcement of the National Medical Products Administration on the Implementation of the 2025 Edition of the Pharmacopoeia of the People's Republic of China (No. 32 of 2025)

Announcement of the National Medical Products Administration on the Implementation of the 2025 Edition of the Pharmacopoeia of the People's Republic of China (No. 32 of 2025)

31

2025

/

03

< 123 >

WhatsApp

5

WhatsApp

86020-8985 8964

E-mial

8

E-mial

pvreport@bio-current.com

Tel

9

Tel

86020-8985 8964


R & D Center

Address: Room 803, Building B3, Science and Technology Enterprise Accelerator, No.11 Kaiyuan Avenue, Huangpu District, Guangzhou

Telephone:020-8985 8964

Production Base

Address: No.80, Spring Equinox Road, Huangpu District, Guangzhou

Telephone:020-8328 9091

Adverse Drug Reaction/Event Feedback E-mail:pvreport@bio-current.com

er

   WeChat 

  • Home

  • About Us

    • Company Profile

    • Development Process

    • Strength

    • Enterprise Culture

  • Products

    • Listed Products

    • Linked API

    • Pipeline

  • Custom Services

    • Process Transfer

    • Process Validation and Registration Declaration

    • Analysis and Testing

    • API Production

  • Blog

    • Company News

    • EHS Information

    • Industry News

  • Join us

    • Recruitment Posts

    • Employee Benefits

    • Employee Activities

  • Contact Us

Copyright©2024 All Rights Reserved of Guangzhou Keruite Pharmaceutical Co., Ltd.

www.300.cn  SEO

Business License